Editas Medicine (EDIT) Price & Analysis

Compare

3,552 Followers

EDIT Stock Chart & Stats

$2.03

-$0.10(-7.24%)

At close: Jan 08 4:00 PM EST

$2.03

-$0.10(-7.24%)

Day’s Range― - ―

52-Week Range$0.91 - $4.54

Previous CloseN/A

Volume963.61K

Average Volume (3M)1.70M

Market Cap

$198.17M

Enterprise Value$52.17M

Total Cash (Recent Filing)$165.65M

Total Debt (Recent Filing)$19.65M

Price to Earnings (P/E)―

Beta2.13

Next Earnings

Feb 19, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding97,618,660

10 Day Avg. Volume1,781,207

30 Day Avg. Volume1,697,905

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.78

Price to Sales (P/S)3.24

P/FCF Ratio-0.48

Enterprise Value/Market Cap0.26

Enterprise Value/Revenue1.12

Enterprise Value/Gross Profit1.12

Enterprise Value/Ebitda-0.30

Forecast

1Y Price Target

$4.02

Price Target Upside98.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.09

Revenue Forecast (FY)$15.43M

Bulls Say, Bears Say

Bulls Say

Business-development AppealStrong efficacy in validated LDLR biology positions the program as an attractive business-development candidate for larger pharmaceutical companies pursuing cardiometabolic gene medicines.

Clinical Proof-of-concept TimingAnalyst highlights expected proof-of-concept clinical data in 2026 for the in vivo LDLR-targeting program, which could validate the mechanism in patients and re-rate the asset.

Preclinical EfficacyPreclinical data show approximately 90% reduction in LDL cholesterol in non-human primate and mouse models after a single dose, indicating a potentially transformative effect versus existing lipid-lowering therapies.

Bears Say

Competitive DifferentiationAnalyst notes the program lacks clear differentiation from a competing in vivo editor aside from the editing machinery, which could limit market share and partnership leverage.

Liver Safety SignalTransient elevations in liver enzymes were observed after treatment, which may prompt closer regulatory scrutiny and additional safety monitoring in clinical trials.

Preclinical-to-clinical Translation RiskHeavy reliance on animal model results creates translation risk because human responses to in vivo gene editors can differ, potentially diminishing expected clinical benefits.

Editas Medicine News

Editas Medicine price target lowered to $3.50 from $12 at Chardan

Chardan lowered the firm’s price target on Editas Medicine (EDIT) to $3.50 from $12 and keeps a Buy...

2M ago

EDIT

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

2M ago

AZN

BMY

Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties

JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating today. Soumit...

2M ago

EDIT

Editas Medicine Reports Q3 2025 Progress and Financials

Editas Medicine Inc. ( ($EDIT) ) has released its Q3 earnings. Here is a breakdown of the information...

2M ago

EDIT

Editas Medicine price target raised to $4.60 from $4 at Clear Street

Clear Street raised the firm’s price target on Editas Medicine (EDIT) to $4.60 from $4 and keeps a...

2M ago

EDIT

Editas Medicine reports Q3 EPS (28c), consensus (38c)

Reports Q3 revenue $7.54M, consensus $4.94M. “We are incredibly excited by the progress we made in the third...

2M ago

EDIT

Editas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet

Editas Medicine Inc. (EDIT) is scheduled to report 3rd quarter earnings on 11/10/2025. Regarding Q3 estimates, Wall Street...

2M ago

EDIT

FDA to speed up gene editing therapy approvals, Bloomberg reports

The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients...

3M ago

CRSP

EDIT

Video: This stock is dragging down the in vivo gene editing therapy space

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

3M ago

MGX

BEAM

Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies

Editas Medicine Inc. (($EDIT)) announced an update on their ongoing clinical study. Study Overview: Editas Medicine Inc. is...

3M ago

EDIT

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30...

3M ago

MGX

CRSP

Intellia Therapeutics price target lowered to $30 from $36 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy...

3M ago

BEAM

CRBU

Editas Medicine management to meet with Cantor

Meeting to be held in Denver on October 27 and in San Francisco on October 28 hosted by...

3M ago

EDIT

Editas Medicine Unveils Promising Preclinical Data on EDIT-401

Editas Medicine ( ($EDIT) ) has provided an update. On October 9, 2025, Editas Medicine presented in vivo...

3M ago

EDIT

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $0.91 and its highest was $4.54 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $198.17M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Feb 19, 2026 which is in 31 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Nov 10, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.016.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.23.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 97,618,660 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went up 2.024%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-211.37%

Trailing 12-Months

Asset Growth

-38.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$4.02

▲(98.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.02,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.05,2.276923076923077,2.503846153846154,2.730769230769231,2.957692307692308,3.184615384615385,3.4115384615384614,3.6384615384615384,3.8653846153846154,4.092307692307692,4.319230769230769,4.546153846153846,4.773076923076923,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.05,2.2015384615384614,2.353076923076923,2.5046153846153842,2.656153846153846,2.8076923076923075,2.9592307692307687,3.1107692307692303,3.262307692307692,3.4138461538461535,3.565384615384615,3.7169230769230763,3.868461538461538,{"y":4.02,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.05,2.123076923076923,2.196153846153846,2.269230769230769,2.342307692307692,2.4153846153846152,2.4884615384615385,2.5615384615384613,2.6346153846153846,2.707692307692308,2.7807692307692307,2.853846153846154,2.926923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.05,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >